Mark Pimentel, MD, FRCP(C) to Review IBS-C Patient Data from Two SYN-010 Phase 2 Clinical Trials
Conference Call Scheduled on Monday, May 23, 2016, at 8:30 a.m. (EDT)
Rockville, MD, May 17, 2016 – Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that the Company is scheduled to host a conference call on Monday, May 23, 2016, at 8:30 a.m. (EDT) to review IBS-C patient data from the first and second Phase 2 clinical trials for SYN-010. Synthetic Biologics previously reported positive topline data from both Phase 2 clinical trials, including a reduction in breath methane levels, abdominal pain and bloating, and an increase in the frequency of complete spontaneous bowel movements.
During the call, Dr. Mark Pimentel, Director of the GI Motility Program and Laboratory at Cedars-Sinai, intends to recap the SYN-010 results to be included in the poster presentation at Digestive Disease Week® (DDW® 2016) on Sunday, May 22, 2016 in San Diego. The dial-in information for the call is as follows:
U.S. toll free: 1-888-347-5280
International: +1 412-902-4280.
Participants are asked to dial in 15 minutes before the start of the call to register. The call and associated slide presentation will be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/14387. An archive of the call will be available for approximately six months at the same URL https://www.webcaster4.com/Webcast/Page/1096/14387 beginning approximately one hour after the call's conclusion. About SYN-010
SYN-010 is a proprietary, modified-release formulation of lovastatin lactone that is intended to reduce methane production by certain microorganisms (M. smithii) in the gut while minimizing disruption to the microbiome to treat an underlying cause of IBS-C. SYN-010 is intended to act primarily in the intestinal lumen while avoiding systemic absorption, thereby targeting a major cause of IBS-C, not just the symptoms. To access the SYN-010 mechanism of action video on Synthetic Biologics’ website, please click here. About Synthetic Biologics, Inc. Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead candidates in Phase 2 development are: (1) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and (2) SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD). In collaboration with Intrexon Corporation, the Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.
Conference Call Scheduled on Monday, May 23, 2016, at 8:30 a.m. (EDT)
Rockville, MD, May 17, 2016 – Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that the Company is scheduled to host a conference call on Monday, May 23, 2016, at 8:30 a.m. (EDT) to review IBS-C patient data from the first and second Phase 2 clinical trials for SYN-010. Synthetic Biologics previously reported positive topline data from both Phase 2 clinical trials, including a reduction in breath methane levels, abdominal pain and bloating, and an increase in the frequency of complete spontaneous bowel movements.
During the call, Dr. Mark Pimentel, Director of the GI Motility Program and Laboratory at Cedars-Sinai, intends to recap the SYN-010 results to be included in the poster presentation at Digestive Disease Week® (DDW® 2016) on Sunday, May 22, 2016 in San Diego. The dial-in information for the call is as follows:
U.S. toll free: 1-888-347-5280
International: +1 412-902-4280.
Participants are asked to dial in 15 minutes before the start of the call to register. The call and associated slide presentation will be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/14387. An archive of the call will be available for approximately six months at the same URL https://www.webcaster4.com/Webcast/Page/1096/14387 beginning approximately one hour after the call's conclusion. About SYN-010
SYN-010 is a proprietary, modified-release formulation of lovastatin lactone that is intended to reduce methane production by certain microorganisms (M. smithii) in the gut while minimizing disruption to the microbiome to treat an underlying cause of IBS-C. SYN-010 is intended to act primarily in the intestinal lumen while avoiding systemic absorption, thereby targeting a major cause of IBS-C, not just the symptoms. To access the SYN-010 mechanism of action video on Synthetic Biologics’ website, please click here. About Synthetic Biologics, Inc. Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead candidates in Phase 2 development are: (1) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and (2) SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD). In collaboration with Intrexon Corporation, the Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.
